Latest / Breaking News To Trading Moves
Tavneos Safety Hazards and Biotech Market Repercussions
In this episode of Breaking News to Trading Moves, we look at the market impact of new safety concerns around Amgen’s rare disease drug Tavneos. The news says around 20 deaths linked to serious liver dysfunction have been reported in Japan among patients treated with Tavneos. Kissei, Amgen’s partner in Japan, has asked doctors to stop prescribing the drug to new patients because of liver damage concerns.
For traders, this is not only an $AMGN story. It is a reminder that drug safety can quickly change the valuation of a healthcare theme. Rare disease drugs often trade on strong pricing power…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.